Daraxonrasib Nearly Doubles Survival in Pancreatic Cancer
Daraxonrasib, also known as RMC-6236, nearly doubled survival in a phase 3 metastatic pancreatic cancer trial, but it remains experimental.
Our Hub Medical Articles
1
Active articles
1
Writing doctors
1
Categories
30
Total reads
Showing 1 of 1 articles